Additionally, the relationship between immunological check-point markers and PD-L1 expression suggests that PD-L1 has a function in controlling tumor immunology in malignancies, particularly in BRCA, PRAD, LUAD, BLCA, and OV. This evidence concerns the gene CD274 and neoplasm.